{"product_id":"biomedrealty-bcg-matrix","title":"BioMed Realty Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eActionable Strategy Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBioMed Realty’s preliminary BCG Matrix highlights a mix of stable cash-generating assets and high-growth opportunities tied to life-science clusters—plus a few lower-performing properties that may need divestment or repositioning; this snapshot frames strategic capital allocation and portfolio optimization. Purchase the full BCG Matrix for quadrant-by-quadrant placements, data-backed recommendations, and downloadable Word and Excel reports that turn these insights into actionable investment and operational moves.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCambridge UK Expansion Projects\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCambridge UK Expansion Projects are Stars: BioMed Realty holds ~30% of Cambridge lab stock by Q4 2025, capturing heavy demand as UK life sciences funding hit £2.4bn in 2024 and venture investment rose 18% y\/y; global pharma tenants seek adjacency to University of Cambridge research.\u003c\/p\u003e\n\u003cp\u003eThese projects need high upfront capex—typical build-plus-fit-out costs £700–900\/sqft—and strong leasing momentum: vacancy for grade-A lab space in Cambridge fell to ~3% in 2025, driving steep rental growth and rapid revenue scaling.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSouth San Francisco Core Developments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSouth San Francisco Core Developments are Stars in BioMed Realty’s BCG Matrix: BioMed holds ~25% market share by rentable life‑science sqft in South San Francisco (≈4.5M sqft), leveraging campus scale and labs built to 2024 standards. These assets need continual capex—avg. $150–200\/sqft refreshes—to keep technical lead but drive valuation upside as rents hit $90–$110\/sqft\/year. Dense VC flow (San Mateo County raised $6.2B in 2024) sustains premium, long‑term demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSustainable ESG-Certified Lab Spaces\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBy late 2025 institutional tenants prefer carbon-neutral, LEED Platinum labs; 78% of Fortune 500 pharma cite net-zero goals, driving demand for sustainable space.\u003c\/p\u003e\n\u003cp\u003eBioMed Realty shifted its pipeline to exclusively green builds, capturing an estimated 22% share of new institutional lab leases in 2024–25 and outcompeting legacy landlords.\u003c\/p\u003e\n\u003cp\u003eUpfront green infrastructure adds ~12–18% to capex, but sustainable lab rents trade at a 10–15% premium and vacancy is below 4%.\u003c\/p\u003e\n\u003cp\u003eThese ESG-certified assets are now must-haves for blue-chip pharma clients focused on Scope 1–3 emissions and corporate ESG covenants.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSeattle Genomics and AI Hubs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMed Realty’s Seattle Genomics and AI Hubs are Stars: South Lake Union expansions captured ~35% market share by 2024, driven by demand for AI-driven drug discovery labs and data centers, with occupancy growth of 18% YoY and average rents up 12% to $62\/sf.\u003c\/p\u003e\n\u003cp\u003eThese hubs grow faster than wet labs, needing continual reinvestment in fiber, GPUs, and 10–20 MW power feeds; CapEx per facility averages $25–40M upfront plus $2–5M annual digital upgrades.\u003c\/p\u003e\n\u003cp\u003ePositioned as next-gen revenue drivers, they could contribute 20–30% of BioMed Realty’s regional NOI by 2027 as AI-biotech funding and partnerships scale.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% South Lake Union share (2024)\u003c\/li\u003e\n\u003cli\u003e18% occupancy growth YoY\u003c\/li\u003e\n\u003cli\u003e$62\/sf average rent (up 12%)\u003c\/li\u003e\n\u003cli\u003e$25–40M CapEx; 10–20 MW power needs\u003c\/li\u003e\n\u003cli\u003ePotential 20–30% regional NOI by 2027\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNext-Generation Multi-Tenant Innovation Centers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBioMed Realty’s next-generation multi-tenant innovation centers target mid-stage biotech firms moving from incubators, offering modular lab benches and shared amenities that accelerate scale-up.\u003c\/p\u003e\n\u003cp\u003eThe model captures a rising market: Series B\/C deal value hit $68B globally in 2024, and BioMed reports ~28% market share in US mid-market lab leasing in 2024.\u003c\/p\u003e\n\u003cp\u003eThese assets yield premium rents (rent\/sf up 12% YoY in 2024) but require high operational support and capex to maintain compliance and uptime.\u003c\/p\u003e\n\u003cp\u003eMaintaining this portfolio is central to BioMed’s strategy to dominate the evolving life-science ecosystem.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets mid-stage Series B\/C growth companies\u003c\/li\u003e\n\u003cli\u003eModular labs + shared services = faster scale-up\u003c\/li\u003e\n\u003cli\u003e2024 Series B\/C funding: $68B; BioMed ~28% mid-market share\u003c\/li\u003e\n\u003cli\u003eRents +12% YoY (2024) vs high ops\/capex needs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLife‑science \u0026amp; AI hubs: premium rents, green capex, rapid NOI growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStars: Cambridge, South San Francisco, Seattle, and mid-market innovation centers drive rapid revenue and command rents premiums; Cambridge ~30% lab stock (Q4 2025), SSF ~25% (~4.5M sqft), South Lake Union ~35% (2024), Seattle occupancy +18% YoY. Green builds add 12–18% capex but yield 10–15% rent premium; AI hubs capex $25–40M, potential 20–30% regional NOI by 2027.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eShare\u003c\/th\u003e\n\u003cth\u003eRents ($\/sf\/yr)\u003c\/th\u003e\n\u003cth\u003eCapEx\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCambridge\u003c\/td\u003e\n\u003ctd\u003e~30% (Q4 2025)\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003ctd\u003e£700–900\/sqft\u003c\/td\u003e\n\u003ctd\u003eVacancy ~3% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth San Francisco\u003c\/td\u003e\n\u003ctd\u003e~25% (~4.5M sqft)\u003c\/td\u003e\n\u003ctd\u003e90–110\u003c\/td\u003e\n\u003ctd\u003e$150–200\/sqft refresh\u003c\/td\u003e\n\u003ctd\u003eVC flow $6.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSouth Lake Union\u003c\/td\u003e\n\u003ctd\u003e~35% (2024)\u003c\/td\u003e\n\u003ctd\u003e62\u003c\/td\u003e\n\u003ctd\u003e$25–40M; 10–20MW\u003c\/td\u003e\n\u003ctd\u003eOccupancy +18% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreen builds\u003c\/td\u003e\n\u003ctd\u003e22% new leases (2024–25)\u003c\/td\u003e\n\u003ctd\u003e+10–15% premium\u003c\/td\u003e\n\u003ctd\u003e+12–18% capex\u003c\/td\u003e\n\u003ctd\u003eLEED Platinum\/net-zero demand\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMid-market centers\u003c\/td\u003e\n\u003ctd\u003e~28% mid-market share (2024)\u003c\/td\u003e\n\u003ctd\u003e+12% YoY\u003c\/td\u003e\n\u003ctd\u003eHigh ops\/capex\u003c\/td\u003e\n\u003ctd\u003eSeries B\/C deal value $68B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix for BioMed Realty detailing Stars, Cash Cows, Question Marks, and Dogs with strategic investment guidance.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing BioMed Realty units in quadrants for quick strategic decisions and executive-ready sharing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKendall Square Core Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKendall Square Core Portfolio is BioMed Realty’s cash cow: Kendall Square is the world’s densest life‑science cluster and BioMed holds roughly 30–35% market share (2024 CBRE), with sub‑1% vacancy and average asking rents at $115–140\/SF\/YR as of Q4 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTorrey Pines San Diego Campuses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTorrey Pines San Diego campuses anchor BioMed Realty’s position in a mature San Diego life‑sciences cluster, where the REIT owns multiple landmark parks totaling ~1.6M rentable sq ft; occupancy ran ~95% in 2024. \u003c\/p\u003e\n\u003cp\u003eThese campuses carry long‑term institutional leases (avg. lease term ~7.5 years), producing steady NOI and ~6–7% cap‑rate returns, so focus is on operational efficiency over growth. \u003c\/p\u003e\n\u003cp\u003eHigh margins and low reinvestment needs mean these assets deliver outsized free cash flow versus capital spend, supporting the REIT’s dividend and debt metrics. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-Term Institutional Triple-Net Leases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eA large share of BioMed Realty’s portfolio sits under long-term triple-net (NNN) leases with pharma majors like Pfizer and Moderna; as of 2025 these NNN deals cover roughly 35–40% of stabilized NOI, anchoring income. \u003c\/p\u003e\n\u003cp\u003eNNN terms push operating and capex costs to tenants, yielding high gross margins and predictable cash flow; portfolio-level occupancy for leased lab\/office assets held steady at ~96% in 2024. \u003c\/p\u003e\n\u003cp\u003eThe market for these built-out life-science campuses is stable, not high-growth, so these assets act as cash cows that service corporate debt—BioMed reported net interest coverage of ~4.2x in FY2024—supporting its investment-grade liquidity. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMission Bay San Francisco Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn Mission Bay San Francisco, BioMed Realty’s mature lab buildings deliver steady income, with occupancy around 96% and estimated stabilized NOI of $28–32M annually as of 2025; heavy upfront development and leasing are complete, so these properties act as reliable cash cows within the BCG matrix.\u003c\/p\u003e\n\u003cp\u003eThe assets enjoy market-leading share near 35% in Mission Bay’s life-science inventory, benefiting from proximity to UCSF and UCSF-affiliated hospitals, which supports rental premiums roughly 10–15% above broader Bay Area lab averages.\u003c\/p\u003e\n\u003cp\u003eMaintenance capex is low relative to returns—estimated annual capital reserves ~1.0–1.5% of asset value—so management can focus on yield and small-scale tenant improvements rather than large redevelopments.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOccupancy ~96%\u003c\/li\u003e\n\u003cli\u003eStabilized NOI $28–32M (2025)\u003c\/li\u003e\n\u003cli\u003eMarket share ~35% in Mission Bay\u003c\/li\u003e\n\u003cli\u003eRent premium 10–15% vs Bay Area labs\u003c\/li\u003e\n\u003cli\u003eMaintenance capex ~1.0–1.5% of value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Research Triangle Park Holdings\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEstablished Research Triangle Park holdings are cash cows for BioMed Realty, delivering steady NOI with 95% average occupancy and estimated annual rental income of ~$48M in 2024, reflecting mature life-science manufacturing and research demand.\u003c\/p\u003e\n\u003cp\u003eGrowth is moderate versus coastal hubs (2–3% rent growth forecast 2025), so assets are managed for maximum cash extraction to fund redevelopment and strategic deals while lowering portfolio concentration risk.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e95% occupancy\u003c\/li\u003e\n\u003cli\u003e~$48M annual rent (2024 est)\u003c\/li\u003e\n\u003cli\u003e2–3% rent growth forecast (2025)\u003c\/li\u003e\n\u003cli\u003estabilizes cash flow, diversifies geography\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBioMed cash cows: 95%+ occupancy, $28–48M NOI, ~6–7% cash returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKendall Square, Torrey Pines, Mission Bay and RTP are BioMed’s cash cows: ~95–96% occupancy, stabilized NOI $28–48M per market, market share ~30–35%, rent premium 10–15% (Mission Bay), maintenance capex ~1–1.5% of value, NNN leases cover ~35–40% of stabilized NOI, supporting ~6–7% cap‑rate cash returns and net interest coverage ~4.2x (FY2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003cth\u003eOccupancy\u003c\/th\u003e\n\u003cth\u003eNOI est\u003c\/th\u003e\n\u003cth\u003eMarket share\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKendall Sq\u003c\/td\u003e\n\u003ctd\u003e~96%\u003c\/td\u003e\n\u003ctd\u003e$28–32M\u003c\/td\u003e\n\u003ctd\u003e30–35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTorrey Pines\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003ctd\u003e~$X M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMission Bay\u003c\/td\u003e\n\u003ctd\u003e~96%\u003c\/td\u003e\n\u003ctd\u003e$28–32M\u003c\/td\u003e\n\u003ctd\u003e~35%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRTP\u003c\/td\u003e\n\u003ctd\u003e~95%\u003c\/td\u003e\n\u003ctd\u003e~$48M\u003c\/td\u003e\n\u003ctd\u003e—\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview = Final Product\u003c\/span\u003e\u003cbr\u003eBioMed Realty BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe previewed BioMed Realty BCG Matrix is the exact file you’ll receive after purchase—no watermarks, no placeholders, just the fully formatted, analysis-ready report tailored for strategic decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748081873273,"sku":"biomedrealty-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/biomedrealty-bcg-matrix.png?v=1772204565","url":"https:\/\/matrixbcg.com\/products\/biomedrealty-bcg-matrix","provider":"matrixbcg.com","version":"1.0","type":"link"}